ResearchType 1 DiabetesIs empagliflozin a disease-modifying therapy for adult-onset type 1 diabetes?
Investigators: A/Prof John Wentworth and Prof Peter Colman Summary: A single-arm safety and feasibility study of 6 months of empagliflozin therapy, started within 100 days of T1D diagnosis. Outcomes include adverse events, glycaemic variability and C-peptide response to mixed meal. Inclusion criteria:
Royal Melbourne Hospital, 300 Grattan Street, Parkville 3050 Recruitment duration: Until participant limit reached. Contact details: A/Prof John Wentworth E: [email protected] M: 0422 992 891 Environmental Determinants of Islet Autoimmunity (ENDIA)
Investigators: Prof Peter Colman, Prof Len Harrison, and A/Prof John Wentworth Summary: ENDIA is the only study in the world to follow children from during pregnancy and is designed to identify the interactions between genes and the environment that are driving the development of type 1 diabetes. Study follow up is flexible but usually 3 monthly during the pregnancy until the child is 24 months, then 6 monthly thereafter. ENDIA is an observational study, without intervention. There is a Regional Participation Program. Inclusion criteria:
Multiple, see study website Recruitment duration: Until mid-2018 with plans to extend recruitment. Children recruited into the study will be followed to adulthood (unless consent withdrawn). Contact details: ENDIA Collaboration E: [email protected] W: http://www.endia.org.au/ Clinician Approaches to Alcohol and Drug Use in T1DM
Investigators: Dr Adam Pastor Summary: We are looking for clinicians to complete a survey on their approaches to alcohol and drug use when working with young adults with type 1 diabetes as part of a broader study in to the impact of alcohol and drug use on glycemic control in this cohort. The work is being down through University of Melbourne and St Vincent’s Hospital Melbourne. The feedback should in turn assist in developing services for this cohort and informing guidelines. If you are one of the following:
If you would like any more information on the study please contact Dr Adam Pastor at [email protected] or (03) 9231 2627. Type 2 DiabetesA randomised controlled study aimed to normalise glycaemia using triple therapy in newly diagnosed patients with type 2 diabetes
Investigators: Rufi Chen, Dr Elif Ekinci Summary: This is a pilot randomised controlled study at Austin Health, to determine whether normalisation of glycaemia with triple therapy (metformin, saxagliptin and dapagliflozin) as compared to initial monotherapy with metformin and sequential dapagliflozin, is safe and will lead to improvements in beta cell function in newly diagnosed T2DM. Participants are required to attend 5 study visits over 12 months with study investigations including blood tests, urine tests, and 2 mixed meal tests. Inclusion criteria:
Repatriation Hospital, Austin Health, Heidelberg, Victoria. Recruitment duration: Until end 2018. Contact details: Rufi Chen E: [email protected] M: 0403 554 400 OsteoporosisThe Efficacy of Denosumab in Preventing Bone Microstructural Decay in Premenopausal Women with Early Breast Cancer Being Treated with Ovarian Suppression and Aromatase Inhibition - A Randomised Controlled Trial
Investigators: Dr Sabhashini Ramchand, Prof Mathis Grossmann, Prof Ego Seeman, and Prof Jeffrey Zajac Summary: -In premenopausal women with early ER-positive breast cancer, combined ovarian suppression and aromatase inhibition result in a precipitous decline in oestradiol production. This is likely to lead to bone loss and increased fracture risk in these young women. The aim of this study is to evaluate the efficacy of denosumab, initiated at the start of ovarian suppression, in preventing bone microstructural decay. We will use a novel imaging tool, HRpQCT, to analyse bone microstructure. -Participants are required to have 4 study visits over 12 months with study investigations including DEXA, HR-pQCT, blood tests, questionnaires, and medical reviews. Inclusion criteria:
Study site: Austin Hospital, 145 Studley Road, Heidelberg, Victoria. Recruitment duration: Until end 2018. Contact details: Dr Sabashini Ramchand E: [email protected] M: 0478 168 578 F: 9496 2980 (attention: Dr S Ramchand) Effects of cross-sex hormone therapy on bone microarchitecture in transgender individuals
Investigators: Dr Ingrid Bretherton, Dr Ada Cheung, Prof Mathis Grossmann, and Prof Jeffrey Zajac Summary: We are running a prospective longitudinal as well as a cross sectional study looking at the impact of cross sex hormones on bone health, body composition, and metabolic risk. The prospective study involves 5 study visits over 2 years. The cross sectional study involves a single study visit. Each study visit involves a blood test, a DXA and HR-pQCT scan. These are both low radiation scans (not above background levels of radiation exposure). All study visits are at the Repatriation Hospital. Inclusion criteria:
Repatriation Hospital, Austin Health Recruitment duration: Prospective: until end 2019, Cross sectional: until early 2018 Contact details: Dr Ingrid Bretherton E: [email protected] P: 9496 2486 Gonadal DysfunctionBiological actions of estradiol in men
Investigators: Dr Nick Russell, Prof Mathis Grossmann, Prof Ego Seeman, Prof Richard Kanaan, Prof David Handelsman, Dr Daryl Lim-Joon, Mr Ali Ghasem-Zadeh, and Dr Michael Ching Summary: A 6-month randomised placebo-controlled trial of transdermal estradiol add-back in men undergoing androgen deprivation therapy (ADT) for prostate cancer. We hypothesise that this intervention will mitigate some of the adverse bone and metabolic effects of ADT. Aims: To assess, in men receiving ADT, the effects of transdermal estradiol add-back on:
Austin Health (4 study visits over 6 months) Recruitment duration: Until participant limit reached. Contact details: Dr Nick Russell E: [email protected] P: 0422 992 628 |
|